Clinical Scorecard: Independent Risk Factors for Ticagrelor-Induced Dyspnea in Patients with Acute Coronary Syndrome: The Role of Plasma Concentration, Metabolite Ratio, and LDH Levels
At a Glance
Category
Detail
Condition
Ticagrelor-induced dyspnea
Key Mechanisms
Plasma concentration of ticagrelor, metabolite ratio, and LDH levels
Target Population
Patients with acute coronary syndrome (ACS)
Care Setting
Inpatient care for ACS
Key Highlights
Ticagrelor-induced dyspnea occurs in 6% to 20% of patients.
Higher peak ticagrelor concentration is associated with increased risk of dyspnea.
Lower LDH levels and ticagrelor metabolite ratio are linked to dyspnea development.
Older age, male gender, and history of asthma are potential predictors of dyspnea.
Therapeutic drug monitoring of ticagrelor is emphasized for individualized treatment.
Guideline-Based Recommendations
Diagnosis
Dyspnea assessed using the modified Borg scale.
Management
Consider switching to an alternative P2Y12 inhibitor if dyspnea occurs.
Monitoring & Follow-up
Monitor plasma concentrations of ticagrelor and its active metabolite.
Risks
Increased risk of dyspnea with higher ticagrelor concentrations.
Patient & Prescribing Data
102 inpatients with ACS receiving dual antiplatelet therapy.
Standard therapy includes ticagrelor (90 mg twice daily) and aspirin (100 mg once daily).
Clinical Best Practices
Individualize antithrombotic strategies based on patient characteristics.
Utilize therapeutic drug monitoring to optimize ticagrelor dosing.
